Analyst’s view
While the results are preliminary, we find the data promising as it not only reinforces the competitive advantage seen with ADAPT treated tissue (ie effective, safe, strong, biocompatible and easy to use), but it also expands the potential market opportunity for the platform technology into TBI, a sizable US market (ie 1.7m TBI and 275k hospitalisations/annum) with unmet medical need.
Price Target - $0.22
Please contact Campbell Harris or I to discuss your participation in the offer or if you would like to view additional research reports.
[attachment "AHZ150302_Heart of the matter.pdf" deleted by Morgan Shipp/Morgans/AU]
Regards,
Morgan Shipp LLB, BComm
Stockbroker | Authorised Representative: 355749
Level 9 Aurora Place 88 Phillip Street Sydney NSW 2000
GPO Box 5385 Sydney NSW 2001
AHZ Price target $0.22 by Morgan
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
-0.050(0.25%) |
Mkt cap ! $387.7M | |||
| Open | High | Low | Value | Volume |
| $20.20 | $20.50 | $20.00 | $71.28K | 3.532K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 776 | $20.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.18 | 1200 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.16 |
Change
-0.050 ( 0.69 %) |
||||
| Open | High | Low | Volume | ||
| $20.17 | $20.17 | $20.09 | 129 | ||
| Last updated 15.56pm 16/05/2024 ? | |||||
| AVR (ASX) Chart |